Skip to main content

Table 1 Incidence and hazard ratio for revision hip replacement and associated risk factor

From: Disorder-related risk factors for revision total hip arthroplasty after hip hemiarthroplasty in displaced femoral neck fracture patients: a nationwide population-based cohort study

 

n

(%)

Event no.

PY

Ratea

Crude HR (95 % CI)

Adjusted HR (95 % CI)

Total

68,030

 

1114

238,875

4.66

  

Age, year

 20–29

53

(0.08)

9

260

34.57

30.9 (13.4–71.5)***

23.6 (10.2–54.7)***

 30–39

158

(0.23)

11

832

13.23

12.0 (5.43–26.4)***

8.52 (3.85–18.9)***

 40–49

499

(0.73)

25

2302

10.86

9.49 (4.93–18.3)***

6.90 (3.56–13.4)***

 50–59

1862

(2.74)

63

7908

7.97

6.65–3.73 (11.9)***

5.48 (3.06–9.82)***

 60–69

10,492

(15.4)

257

45,526

5.65

4.77 (2.79–8.17)***

4.35 (2.54–7.46)***

 70–79

26,868

(39.5)

458

101,757

4.50

3.59 (2.11–6.12)***

3.38 (1.99–5.76)***

 80–89

24,095

(35.4)

277

71,159

3.89

2.80 (1.64–4.80)***

2.73 (1.60–4.68)***

 ≥90

4003

(5.88)

14

9132

1.53

1.00

1.00

 Mean (SD)

77.3

(9.26)

     

Gender

 Women

44,241

(65.0)

614

163,685

3.75

1.00

1.00

 Men

23,789

(35.0)

500

75,190

6.65

1.69 (1.50–1.90)***

1.58 (1.40-1.78)***

Comorbidity

 Diabetes

  No

51,877

(76.3)

861

191,518

4.50

1.00

 

  Yes

16,153

(23.7)

253

47,357

5.34

1.09 (0.95–1.26)

 

 Osteoporosis

  No

64,702

(95.1)

1057

228,211

4.63

1.00

 

  Yes

3328

(4.89)

57

10,664

5.35

1.11 (0.85–1.45)

 

 RA

  No

67,472

(99.2)

1099

236,796

4.64

1.00

 

  Yes

558

(0.82)

15

2079

7.21

1.57 (0.94–2.61)

 

 Cancer

  No

62,848

(92.4)

1038

226,145

4.59

1.00

 

  Yes

5182

(7.62)

76

12,730

5.97

1.14 (0.90–1.44)

 

 COPD

 

  No

60,853

(89.4)

1008

219,410

4.59

1.00

 

  Yes

7177

(10.6)

106

19,465

5.45

1.07 (0.88–1.31)

 

 ESRD

 

  No

66,073

(97.1)

1068

234,698

4.55

1.00

1.00

  Yes

1957

(2.88)

46

4177

11.01

1.99 (1.48–2.68)***

1.74 (1.29–2.34)***

 SLE

  No

67,963

(99.9)

1112

238,679

4.66

1.00

 

  Yes

67

(0.10)

2

196

10.19

2.03 (0.51–8.14)

 

 Ankylosing spondylitis

  No

64,346

(94.6)

1059

228,091

4.64

1.00

 

  Yes

3684

(5.42)

55

10,785

5.10

1.02 (0.78–1.34)

 

 Extrinsic asthma

  No

67,850

(99.7)

1112

238,299

4.67

1.00

 

  Yes

180

(0.26)

2

576

3.47

0.72 (0.18–2.89)

 

 HIV

  No

68,022

(99.9)

1114

238,853

4.66

1.00

 

  Yes

8

(0.01)

0

22

0.00

––

 

 Atherosclerosis

  No

67,550

(99.3)

1106

237,521

4.66

1.00

 

  Yes

480

(0.71)

8

1355

5.91

1.17 (0.58–2.35)

 

 Psoriasis

  No

67,898

(99.8)

1112

238,505

4.66

1.00

 

  Yes

132

(0.19)

2

370

5.40

1.09 (0.27–4.36)

 

 Viral hepatitis

  No

66,212

(97.3)

1080

234,523

4.61

1.00

1.00

  Yes

1818

(2.67)

34

4353

7.81

1.46 (1.04–2.06)*

1.30 (0.92–1.83)

 Depression

  No

66,091

(97.2)

1081

232,874

4.64

1.00

 

  Yes

1939

(2.85)

33

6002

5.50

1.12 (0.79–1.59)

 

 Schizophrenia

  No

67,399

(99.1)

1088

236,468

4.60

1.00

1.00

  Yes

631

(0.93)

26

2408

10.80

2.43 (1.65–3.58)***

1.88 (1.26–2.79)**

 Heart failure

  No

62,500

(91.9)

1035

22,478

4.59

1.00

 

  Yes

5530

(8.13)

79

13,397

5.90

1.11 (0.89–1.40)

 

 UTI

  No

55,877

(82.1)

936

204,007

4.59

1.00

 

  Yes

12,153

(17.9)

178

34,869

5.10

1.2 (0.87–1.19)

 

 Ischemic heart disease

  No

55,681

(81.9)

915

203,038

4.51

1.00

 

  Yes

12,349

(81.9)

199

35,837

5.55

1.13 (0.97–1.32)

 

 Dementia

  No

65,633

(96.5)

1091

231,906

4.70

1.00

1.00

  Yes

2397

(3.52)

23

6969

3.30

0.65 (0.43–0.98)*

0.71 (0.47–1.07)

  1. PY person-years, HR hazard ratio, CI confidence interval, SD standard deviation, RA rheumatoid arthritis, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease, SLE systemic lupus erythematosus, HIV human immunodeficiency virus, UTI urinary tract infection
  2. *p < 0.05; **p < 0.01; ***p < 0.001
  3. aPer 1000 person-years